The Tiziana share price is currently $0.92. This is a decrease of $0.02 from yesterday’s close of $0.94.
It has been a roller-coaster ride for shareholders of Tiziana Life Sciences plc (NASDAQ:TLSA) over the past year. The stock is down almost 60% from its 52-week high, and recent events have only added to the uncertainty surrounding the company.
The most recent development was the ousting of CEO Stefano Pessina, who had only been on the job for a few months.
This followed news that clinical trials for Tiziana’s flagship drug ForAlz had been put on hold after some patients developed liver problems.
Investors are clearly worried about the future of Tiziana, and with good reason. The company now faces an uphill battle to get its drug approved, and it is running out of money quickly.
With shares trading at around $1.50, there is a real possibility that Tiziana could be delisted from NASDAQ if it doesn’t turn things around soon.
For shareholders, it has been a frustrating and disappointing year. However, there is still hope that Tiziana can turnaround its fortunes and deliver value for investors in the long run.
Tiziana Life Sciences
:
Tiziana Life Sciences is a clinical-stage biotechnology company developing novel small molecule drugs to target disease pathways in oncology, inflammation and neurodegeneration. The company’s most advanced drug candidate, Foralumab, is an anti-PD-L1 antibody being developed as a treatment for a range of cancers.
Tiziana has also completed two Phase 1 clinical trials evaluating its lead compounds in patients with relapsed or refractory solid tumors.
Credit: www.jlcatj.gob.mx
Is Tiziana a Buy?
Tiziana Life Sciences PLC (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biotechnology company focused on identifying and developing first-in-class therapies for inflammatory diseases, cancer and other unmet medical needs, today announced that it has entered into an exclusive worldwide license agreement with Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”) for the development and commercialization of Foralumab (anti-NKG2A), an investigational human monoclonal antibody. Under the terms of the agreement, Tiziana will receive an upfront payment of $5 million and is eligible to receive up to $438 million in milestone payments, as well as tiered double digit royalties on net sales.
In addition, Tiziana has entered into a research collaboration agreement with Kyowa Hakko Kirin under which the parties will jointly conduct Phase 2b/3 clinical trials evaluating Foralumab in combination with axitinib in second line renal cell carcinoma (RCC).
The companies will share costs and profits equally from any commercialization of Foralumab globally.
Will Tiziana Life Sciences Stock Go Up?
It is difficult to predict the future of a publicly traded company with any degree of accuracy. Many factors can affect a company’s stock price, including financial performance, global events, and investor sentiment. That said, Tiziana Life Sciences stock has been on a general upward trend over the past year, and there is no reason to believe that this will not continue in the short-term.
The company has strong fundamentals and is well-positioned to capitalize on growth opportunities in the life sciences sector. As such, it is reasonable to expect that Tiziana Life Sciences stock will continue to rise in value over time.
🔴 Tiziana Life Sciences Ltd ADR TLSA Stock Trading Facts 🔴
Conclusion
Tiziana Life Sciences PLC (NASDAQ: TLSA) stock surged on Tuesday after the company announced that it had entered into an exclusive option and license agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize its lead compound, Foraleza.
The news sent shares of Tiziana up nearly 30% in pre-market trading Tuesday morning. Under the terms of the deal, Pfizer will pay Tiziana an upfront payment of $15 million and could potentially make additional milestone payments totaling up to $505 million.
Foraleza is a first-in-class small molecule that targets CD39/CD73, which are enzymes expressed on the surface of immune cells that play a role in regulating immunosuppression. The compound is currently being studied in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.
“This agreement with Pfizer highlights the potential value of Foraleza as an immuno-oncology therapy,” said Giacomo Di Nepi, CEO of Tiziana Life Sciences.
